Conferences

2–4 June 2015, University of Texas at Austin
Novel Antiviral Therapies for Influenza and Other Respiratory Viruses: Bench to Bedside

The programme will include sessions on:
  • Novel influenza targets: polymerase, nucleoprotein and NS1 inhibitors

  • New inhibitors of influenza NA and M2

  • Inhibitors of HA function: DAS-181; fusion inhibitors; broad spectrum MAbs and smaller molecules targeting the HA stem

  • Antivirals and antibody-based therapies against other seasonal and emerging respiratory viruses

  • Host cell targets and determinants of host susceptibility: factors involved in virus replication or mediating the inflammatory response

  • Combination therapies

  • Clinical endpoints and regulatory issues

http://www.isirv.org/site/index.php/antiviral-home

Back to TopTop